Jun 03, 2026 7:00am EDT FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
May 22, 2026 8:30am EDT FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
May 18, 2026 8:30am EDT FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
May 11, 2026 8:30am EDT FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
May 04, 2026 4:01pm EDT FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
May 04, 2026 8:30am EDT FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
Apr 30, 2026 5:55pm EDT FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
Apr 30, 2026 8:30am EDT FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026